Lilly’s Lechleiter Says R&D Is Company's `Lifeblood’ (Audio)

Eli Lilly & Co. Chief Executive Officer John Lechleiter says five Food and Drug Administration approved molecules will be "the basis for growth" as patents expire. Lilly talks with Bloomberg's Tom Keene, Sara Eisen and Scarlet Fu on Bloomberg Radio's "Bloomberg Surveillance."

(Source: Bloomberg)

Running time 03:40

Bloomberg reserves the right to remove comments but is under no obligation to do so, or to explain individual moderation decisions.

Please enable JavaScript to view the comments powered by Disqus.